Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NZN1
UPID:
IRPL1_HUMAN
Alternative names:
Oligophrenin-4; Three immunoglobulin domain-containing IL-1 receptor-related 2; X-linked interleukin-1 receptor accessory protein-like 1
Alternative UPACC:
Q9NZN1; A0AVG4; Q9UJ53
Background:
Interleukin-1 receptor accessory protein-like 1, also known as Oligophrenin-4, plays a pivotal role in neuronal development. It regulates secretion, presynaptic differentiation, and neurite outgrowth. This protein's ability to modulate N-type voltage-gated calcium channel activity and activate the MAP kinase JNK underscores its significance in neurobiological processes.
Therapeutic significance:
Linked to Intellectual developmental disorder, X-linked 21, Interleukin-1 receptor accessory protein-like 1's dysfunction highlights its potential as a therapeutic target. Understanding its role could open doors to novel strategies for treating intellectual disabilities.